Majedie Asset Management Ltd lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.1% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 3,978 shares of the life sciences company’s stock after buying an additional 81 shares during the period. Majedie Asset Management Ltd’s holdings in Illumina were worth $1,237,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc boosted its holdings in Illumina by 1.8% during the 3rd quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock worth $3,976,649,000 after acquiring an additional 188,516 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in shares of Illumina by 66,581.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after purchasing an additional 10,546,495 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Illumina by 13.5% during the fourth quarter. Jennison Associates LLC now owns 5,479,564 shares of the life sciences company’s stock worth $1,643,486,000 after purchasing an additional 653,348 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Illumina by 10.1% during the fourth quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock worth $555,173,000 after purchasing an additional 170,046 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Illumina during the fourth quarter worth about $514,627,000. 90.80% of the stock is owned by institutional investors.
ILMN traded up $2.50 during midday trading on Thursday, hitting $309.08. The stock had a trading volume of 13,247 shares, compared to its average volume of 988,027. The firm has a market cap of $45.34 billion, a P/E ratio of 53.91, a P/E/G ratio of 2.09 and a beta of 1.15. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.33. Illumina, Inc. has a 1 year low of $261.61 and a 1 year high of $372.61.
In other Illumina news, SVP Omead Ostadan sold 1,260 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $294.62, for a total value of $371,221.20. Following the completion of the sale, the senior vice president now owns 29,534 shares in the company, valued at $8,701,307.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Aimee L. Hoyt sold 298 shares of the business’s stock in a transaction that occurred on Tuesday, February 26th. The shares were sold at an average price of $304.63, for a total value of $90,779.74. Following the completion of the sale, the senior vice president now owns 2,297 shares of the company’s stock, valued at approximately $699,735.11. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,589 shares of company stock valued at $12,964,996. 0.38% of the stock is owned by insiders.
ILMN has been the subject of several recent analyst reports. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $339.00 price objective for the company in a report on Friday, February 22nd. Bank of America reissued a “buy” rating and set a $355.00 price objective on shares of Illumina in a report on Wednesday, January 30th. Canaccord Genuity reissued a “buy” rating and set a $350.00 price objective (down previously from $360.00) on shares of Illumina in a report on Friday, April 26th. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a report on Tuesday, April 16th. Finally, Deutsche Bank lowered Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price for the company. in a research note on Friday, January 25th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $353.58.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: What is a Tariff?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.